Growth Strategy
Overhead view of business people working and funding
Investment$325 million Series C funding in its Arsenal (Biosciences)$325 million Series C funding in its Arsenal (Biosciences)
ArsenalBio, a clinical-stage cell therapy firm focused on CAR-T cell therapies, has closed a series C financing round worth $325 million to advance the company’s pipeline for solid tumors.
Subscribe to Our Newsletters
Stay updated and receive your insights for life sciences investment, innovation and partnering directly in your inbox.